Terumo Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Hikaru Samejima
- Full Time Employees
- 31,185
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 2-44-1, Hatagaya Tokyo TY Japan 151-0072
- IPO Date
- Jun 21, 1982
- Website
- terumo.co.jp
- Similar Companies
- Business
- Terumo Corporation is a global medical technology company primarily engaged in the manufacturing and sale of medical devices and equipment. The company offers a comprehensive range of products including vascular intervention and cardio-surgical devices; infusion systems and disposable medical devices; blood management systems; and general hospital supplies. Its core product portfolio encompasses cardiovascular systems, blood transfusion systems, diabetes care products, and endovascular therapy devices. Terumo serves healthcare providers across multiple regions including Japan, Asia-Pacific, Europe, and the Americas. Founded in 1921 and headquartered in Tokyo, Japan, Terumo operates within the healthcare and medical technology industry, targeting hospitals, clinics, and healthcare professionals. Recent significant developments for Terumo Corporation include strategic partnerships and business expansions aimed at enhancing its product offerings and geographic footprint. In the last 1-2 years, Terumo has focused on advancing its vascular intervention and blood management technologies and expanding its presence in emerging markets. The company has introduced new products such as innovative catheter systems and enhanced blood transfusion equipment. Additionally, Terumo has engaged in acquisitions and collaborations to strengthen its portfolio, optimize its supply chain, and extend its capabilities in minimally invasive therapies and biotherapeutics. No major rebranding or name changes have been reported recently, keeping its established corporate identity intact. Operating through various subsidiaries, Terumo Corporation maintains a robust presence in the global medical devices market. Its strategic focus lies in cardiovascular and interventional systems, general hospital products, and blood management solutions. The company’s commitment to innovation is reflected in its ongoing development of advanced product lines and expansion into new healthcare markets worldwide. Terumo’s comprehensive product solutions serve diverse healthcare needs, including surgical procedures, chronic disease management, and emergency care, establishing it as a pivotal player in the medical technology segment.
Company News
Terumo Corporation (TRUMY) Discusses Technological Capabilities and R&D Strategy for Sustained Competitive Advantage Transcript
Terumo (TRUMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Comparing SS Innovations International (NASDAQ:SSII) and Terumo (OTCMKTS:TRUMY)
Head to Head Survey: Bausch + Lomb (NYSE:BLCO) vs. Terumo (OTCMKTS:TRUMY)
Terumo Corp. (OTCMKTS:TRUMY) Short Interest Down 46.0% in July
Terumo Corporation (TRUMY) Q1 2027 Earnings Call Prepared Remarks Transcript
Terumo (OTCMKTS:TRUMY) Shares Gap Up on Strong Earnings
Lantheus (NASDAQ:LNTH) versus Terumo (OTCMKTS:TRUMY) Critical Review
4 Medical Products Stocks Poised to Win Despite Industry Headwinds
Terumo Corporation (TRUMY) Analyst/Investor Day Transcript
Terumo (OTCMKTS:TRUMY) Shares Gap Down – Here’s Why
Terumo Corporation (TRUMY) Q3 2026 Earnings Call Transcript
Terumo Corporation (TRUMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Comparing Utah Medical Products (NASDAQ:UTMD) and Terumo (OTCMKTS:TRUMY)
Terumo (OTCMKTS:TRUMY) vs. TriSalus Life Sciences (NASDAQ:TLSI) Critical Survey
BioLife Solutions (NASDAQ:BLFS) versus Terumo (OTCMKTS:TRUMY) Financial Review
Brainsway (NASDAQ:BWAY) and Terumo (OTCMKTS:TRUMY) Critical Review
Terumo Corporation (TRUMY) Q2 2026 Earnings Call Transcript
OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of Organ Transplantation
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements